Metastases of prostate cancer express estrogen receptor-beta
Metastases of prostate cancer express estrogen receptor-beta
复制标题
DOI：
10.1016/j.urology.2004.05.036
复制
发表时间：
2004-10-01
期刊：
影响因子：
2.1
通讯作者：
Corey, E
中科院分区：
文献类型：
--
作者：
Lai, JS;Brown, LG;Corey, E
目标。检测雌激素受体- β (ERbeta)在前列腺癌（CaP）转移中的表达，为开展转移性CaP患者雌激素治疗研究提供依据。晚期雄激素不依赖型CaP是目前尚无有效治疗方法的严重健康问题。据报道，雌激素可抑制无雄激素环境中CaP细胞的生长。最近的报道表明，前列腺上皮和原代前列腺癌细胞表达ERbeta，随着前列腺癌的进展，ERbeta的表达降低。有人提出ERbeta可能在前列腺细胞的生长调节中起作用。选择性内质网调节剂靶向内质网可能是治疗先进cap方法的有效方法。应用抗ERbeta抗体GC17在免疫组织化学中对20例CaP死亡患者的CaP转移标本（n = 60）中ERbeta的表达进行了检测，并对ERbeta表达与前列腺特异性抗原水平、放疗和雌激素暴露等临床参数的关系进行了统计分析。所有骨性CaP转移灶（33 / 33）和非骨性CaP转移灶（27 / 27）均检测到核ERbeta染色。然而，在患者之间以及个体患者样本中，免疫反应细胞的百分比（5%至100%）存在很大差异。核ERbeta染色与雌激素暴露呈显著负相关（P = 0.05）。我们的数据显示ERbeta在CaP转移中表达，验证了评估选择性ER调节剂治疗晚期CaP的研究启动。
Objectives. To examine estrogen receptor-beta (ERbeta) expression in prostate cancer (CaP) metastases, thereby providing a basis for conducting estrogen therapy studies in patients with metastatic CaP. Advanced androgen-independent CaP is a serious health problem with no effective treatment at present. Estrogens have been reported to inhibit the growth of CaP cells in androgen-free environments. Recent reports have shown that the prostatic epithelium and primary CaP cells express ERbeta, with decreased expression of ERbeta accompanying CaP progression. It has been proposed that ERbeta may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP.Methods. The anti-ERbeta antibody GC17 was used in immunohistochemistry to characterize the expression of ERbeta in CaP metastasis specimens (n = 60) obtained from 20 patients who had died of CaP. Statistical analyses were performed to evaluate the association of ERbeta expression with clinical parameters, including prostate-specific antigen levels, radiotherapy, and estrogen exposure.Results. Nuclear ERbeta staining was detected in all bone CaP metastases (33 of 33) and nonosseous CaP metastases (27 of 27). However, a large variability in the percentage of immunoreactive cells (5% to 100%) was found among patients, as well as among individual patient samples. A statistically significant negative association between nuclear ERbeta staining and estrogen exposure (P = 0.05) was detected.Conclusions. Our data have shown that ERbeta is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP. (C) 2004 Elsevier Inc.